ReviewCancers2020
Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Effects of Metformin on Risk and Prognosis of Biliary Tract Cancer: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Epidemiological characterization of biliary tract cancer in a real-world cohort of patients from the Spanish TTD-RETUD gastrointestinal registry.ESMO real world data and digital oncology · 2026Article
- Translational and Implementation Barrier in the Management of Biliary Tract Cancer: Diagnostic, Molecular, Therapeutic, and Patient-Centered Challenges.Journal of gastroenterology and hepatology · 2026Review
- ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response.JCO precision oncology · 2026Article
- TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.Journal of gastroenterology · 2026Article
- Carbon dots in cancer therapy: a novel approach to targeted drug delivery and reduced toxicity in gallbladder cancer.Frontiers in chemistry · 2026Review
- Second-Line Treatment in cholangiocarcinoma - Current State of the Art and Future Perspectives.Current treatment options in oncology · 2025Review
- Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer.International journal of clinical oncology · 2024Observational
- Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer.Cancers · 2024Review
- KRAS Allelic Variants in Biliary Tract Cancers.JAMA network open · 2024Article
- Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians' and patients' perspectives.Future oncology (London, England) · 2024Review
- Molecular Profile of Intrahepatic Cholangiocarcinoma.International journal of molecular sciences · 2023Review
- Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.Journal of gastroenterology · 2023Review
- Targeted Therapies in Advanced Cholangiocarcinoma.Life (Basel, Switzerland) · 2023Review
- Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer.World journal of gastrointestinal oncology · 2023Review
- The Role of HER2 Status in the Biliary Tract Cancers.Cancers · 2023Review
- Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis.The oncologist · 2023Article
- Case Report: A novel mixture of dose-fractioned radiation and immunotherapy for treatment of cholangiocarcinoma.Frontiers in immunology · 2023Article
- Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.Current oncology (Toronto, Ont.) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biliary tract cancers (BTCs) are a heterogeneous group of adenocarcinomas that originate from the epithelial lining of the biliary tree. BTCs are characterized by presentation with advanced disease precluding curative surgery, rising global incidence, and a poor prognosis. Chemotherapy is the mainstay of the current treatment, which results in a median overall survival of less than one year, underscoring the need for novel therapeutic agents and strategies. Next-generation sequencing-based molecular profiling has shed light on the underpinnings of the complex pathophysiology of BTC and has uncovered numerous actionable targets, leading to the discovery of new therapies tailored to the molecular targets. Therapies targeting fibroblast growth factor receptor (FGFR) fusion, isocitrate dehydrogenase (IDH) mutations, the human epidermal growth factor receptor (HER) family, DNA damage repair (DDR) pathways, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.